These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37900854)

  • 21. Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia.
    Fujino K; Ureshino H; Yoshida T; Ichinohe T
    Cureus; 2023 May; 15(5):e39481. PubMed ID: 37362503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients.
    Cheng T; Chen Y; Liu Y; Ma X; Zeng C; Chen X; Wang S; Xu Y
    Front Oncol; 2022; 12():922120. PubMed ID: 35912178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC.
    Bailén R; Pascual-Cascón MJ; Guerreiro M; López-Corral L; Chinea A; Bermúdez A; Sampol A; Heras I; García-Torres E; Torres M; Roca JR; Herruzo B; Sanz J; Fonseca M; Herrera P; Colorado M; Bento L; López-Godino O; Martín-Calvo C; Fernández-Caldas P; Marcos-Jubilar M; Sánchez-Ortega I; Solano C; Noriega V; Humala K; Oarbeascoa G; Díez-Martín JL; Kwon M;
    Transplant Cell Ther; 2022 Apr; 28(4):204.e1-204.e10. PubMed ID: 35108627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study.
    Islam N; Reuben JS; Dale J; Coates JW; Sapiah K; Markson FR; Jordan CT; Smith C
    JMIR Cancer; 2024 Aug; 10():e54740. PubMed ID: 39167784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma.
    Tanaka T; Nakamae H; Ito A; Fuji S; Hirose A; Eto T; Henzan H; Takase K; Yamasaki S; Makiyama J; Moriuchi Y; Choi I; Nakano N; Hiramoto N; Kato K; Sato T; Sawayama Y; Kim SW; Inoue Y; Inamoto Y; Fukuda T
    Transplant Cell Ther; 2021 Nov; 27(11):928.e1-928.e7. PubMed ID: 34274491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
    Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
    Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 28. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
    Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
    Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
    Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
    Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
    Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
    Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
    Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
    Waclawiczek A; Leppä AM; Renders S; Stumpf K; Reyneri C; Betz B; Janssen M; Shahswar R; Donato E; Karpova D; Thiel V; Unglaub JM; Grabowski S; Gryzik S; Vierbaum L; Schlenk RF; Röllig C; Hundemer M; Pabst C; Heuser M; Raffel S; Müller-Tidow C; Sauer T; Trumpp A
    Cancer Discov; 2023 Jun; 13(6):1408-1427. PubMed ID: 36892565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.
    Kwon M; Bautista G; Balsalobre P; Sánchez-Ortega I; Montesinos P; Bermúdez A; de Laiglesia A; Herrera P; Martin C; Humala K; Zabalza A; Torres M; Bento L; Corral LL; Heras I; Serrano D; Buño I; Anguita J; Regidor C; Duarte R; Cabrera R; Gayoso J; Diez-Martin JL
    Bone Marrow Transplant; 2017 Aug; 52(8):1138-1143. PubMed ID: 28346415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group.
    Kitamura W; Fujii N; Nawa Y; Fujishita K; Sugiura H; Yoshioka T; Fujiwara Y; Usui Y; Fujii K; Fujiwara H; Asada N; Nishimori H; Matsuoka KI; Maeda Y
    Int J Hematol; 2022 Apr; 115(4):515-524. PubMed ID: 35119651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haploidentical Hematopoietic Stem Cell Transplant Using Post-transplant Cyclophosphamide: A Single-Center Initial Experience in Vietnam.
    Huynh MV; Nguyen QT; Huynh PDV; Hoang ND; Nguyen TH; Phu DC
    Blood Cell Ther; 2021 Nov; 4(4):75-83. PubMed ID: 36714066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies.
    Wada F; Kanda J; Yoshioka S; Ishikawa T; Akasaka T; Ueda Y; Hirata H; Arai Y; Yago K; Anzai N; Watanabe M; Ikeda T; Yonezawa A; Imada K; Itoh M; Kitano T; Takeoka T; Hishizawa M; Nohgawa M; Arima N; Asagoe K; Kondo T; Takaori-Kondo A;
    Transplantation; 2022 Jun; 106(6):1279-1287. PubMed ID: 34935764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies.
    Nakamae H; Okamura H; Hirose A; Koh H; Nakashima Y; Nakamae M; Nishimoto M; Makuuchi Y; Kuno M; Harada N; Takakuwa T; Hino M
    Cell Transplant; 2022; 31():9636897221112098. PubMed ID: 35906755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
    Ido K; Koh H; Hirose A; Seto T; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Nanno S; Nakamae M; Nishimoto M; Nakashima Y; Hino M; Nakamae H
    Transplant Cell Ther; 2022 Jan; 28(1):20.e1-20.e10. PubMed ID: 34607074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.